Skip to content
CancerIndex

Publication

Selective inhibition of BET bromodomains.

Authors not recorded

Nature2010PMID 20871596PMC3010259stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (4)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 4

Curated evidence

Evidence citing this paper (1)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
20871596
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
NUTM1 Fusion1
JQ1NUT CarcinomaALIASPredictiveDSupports Sensitivity Response3accepted
EID1781

Treatment of the patient-derived 797 NMC cell line for 48 hours with JQ1 (500 nM) provoked terminal differentiation which was accompanied by growth arrest and sustained inhibition of proliferation. … (full text at CIViC)

PMID 20871596 · Filippakopoulos et al., 2010 · Open in CIViC

civic